ASSESSING CABERGOLINE RESPONSIVENESS AMONG PATIENTS WITH PITUITARY PROLACTINOMA IN NORTH IRAQ

Volume 14 , Issue 1 , March 2024 , Pages 145-152

Authors

Mazyar Jabbar Ahmed 1

1 Kurdistan Higher Council of Medical Specialti es, Erbil, Kurdistan Region, Iraq.

DOI logo 10.17656/jsmc.10460

Keywords

Abstract

Background
Prolactinoma accounts for roughly half of all pituitary tumours. Dopamine agonists are preferred for the
treatment of prolactinomas.
Objectives
This study aimed to determine the response rate to both biochemical and anatomical decreases in prolactinoma
levels.
Methods
This current study was designed before and after a clinical trial (quasi-experimental study). All cases consulted
the Endocrinology Unit of Razen Private Clinic, Erbil Teaching Hospital, and PAR Private Hospitals for
hyperprolactinemia underwent thorough hormonal and imaging evaluations. Among them, only prolactinoma
cases were selected for the study, which was performed over a one-year duration. Cabergoline tablet was
given in two different oral regimens, 0.5mg/ week or 1 mg/week, in two divided doses according to clinical
evaluation and prolactin hormone level.
Results
Sixty four patients diagnosed with prolactinoma enrolled in the current study. Patients with microadenoma
type responded better to cabergoline therapy than macroadenoma patients. There was no signifi cant association
between sex and cabergoline dose and clinical presentation (p–values ˃ 0.05). The statistically signifi cant
difference in prolactin and tumour size by MRI was observed before and after treatment (p: <0.001).
Conclusion
This study obtained excellent effectiveness and tolerance of cabergoline in the treatment of pathological
hyperprolactinemia. It also demonstrated that very few patients experienced side effects that were intolerable
or insuffi cient clinical response. Patients with hyperprolactinemia due to microprolactinoma got more benefi t
from treatment by cabergoline than those with macroprolactinoma.

Statistics
  • Article view579
  • Downloads9
  • Published at21 March 2024

  • RIS
  • BibTeX
  • EndNote
  • Mendeley
  • APA (7th edition)
  • MLA (9th edition)
  • Chicago
  • Harvard
  • IEEE
  • Vancouver